,

Locoregional-Recurrence in Clinical Utility

Locoregional-Recurrence Risk

A significant association was observed in studies between Breast Recurrence Score results and the risk for locoregional recurrence (LRR), in both node-negative and node-positive patients.1,2 The results of these studies have potential clinical implications for locoregional therapy decisions for patients with node-negative or node-positive ER-positive breast cancer.

  • The Recurrence Score result in node-negative patients was an independent, significant predictor of LRR along with age and type of initial treatment.
  • In the node-positive setting, the Recurrence Score result is an independent predictor of LRR along with number of positive nodes and tumor size. These findings may have clinical implications regarding patient selection for post-mastectomy chest wall and regional nodal radiation therapy (XRT) and post-lumpectomy regional nodal XRT in node-positive, ER-positive patients treated with adjuvant chemo-endocrine therapy.
REFERENCES

  1. Mamounas et al. J Clin Oncol. 2010.
  2. Mamounas et al. J Natl Cancer Inst. 2017.

a. DOI: 10.1056/NEJMoa1804710.

*American Society of Clinical Oncology (ASCO) and ASCO are registered trademarks of ASCO; National Comprehensive Cancer Network (NCCN) and NCCN are registered trademarks of NCCN. ASCO and NCCN do not endorse any product or therapy

Making cancer care smarter.®